01—Abstract
Summary
Summary of the 10-K filed March 12, 2010. Cited figures are marked; the original filing is the authoritative source.
Halozyme Therapeutics, Inc. (NASDAQ: HALO) reported total revenues of $13,671,305a for 2009, up from $8,764,139 in 2008, while its net loss widened to $58,360,523 ($0.67 per share) from $48,654,199 ($0.61 per share).
Revenues under collaborative agreements were $12,700,458,b and product sales were $970,847. Research and development expenses rose to $56,614,266 from $44,232,936, driven mainly by the ultrafast insulin and PEGPH20 programs. The company has never been profitable and had an accumulated deficit of $172,010,145 at December 31, 2009.
The company's business centers on rHuPH20, a recombinant human hyaluronidase enzyme that underpins its Enhanze Technology drug delivery platform and its proprietary programs. Partnerships with F. Hoffmann-La Roche and Baxter Healthcare are the core of its revenue base, and Roche's Phase 3 subcutaneous Herceptin trial began in October 2009.
HYLENEX and Cumulase are its two marketed products, and product sales remain very limited. Cash and cash equivalents were $67,464,506c at year-end, and management stated that current cash is sufficient to fund operations for at least the next twelve months, with anticipated 2010 net cash burn of approximately $40.0 to $45.0 million.
Investors should note that stockholders' equity fell to $6,903,389d from $15,379,996, and that the company expects to raise additional capital, potentially through a universal shelf registration of up to $100.0 million filed in January 2010. The filing also discloses dependence on third-party manufacturers (Avid Bioservices and Cook Pharmica) and partners for product supply and commercialization.
02—Key points
Key Highlights
- Total revenues rose to $13,671,305 in 2009 from $8,764,139 in 2008, with collaborative agreement revenues of $12,700,458.
- Net loss was $58,360,523, or $0.67 per share, compared with $48,654,199, or $0.61 per share, in 2008.
- Research and development expenses increased to $56,614,266 from $44,232,936, mainly reflecting the ultrafast insulin and PEGPH20 programs.
- Cash and cash equivalents totaled $67,464,506 at December 31, 2009; management expects 2010 net cash burn of approximately $40.0 to $45.0 million.
- Stockholders' equity declined to $6,903,389 from $15,379,996, and the accumulated deficit reached $172,010,145.
- Roche began a Phase 3 trial of subcutaneous Herceptin in October 2009, and Baxter launched HYLENEX for pediatric rehydration in October 2009.
- The company filed a $100.0 million universal shelf registration statement in January 2010 and disclosed that it may need to raise additional capital.
03—One dollar
04—Financials
Financial Highlights
Figures from 10-KFY2009filed March 12, 2010Financial Statements
05—Questions
Frequently Asked Questions
Is Halozyme profitable, and how large are its losses?
No. The filing states that the company has never been profitable. It reported a 2009 net loss of $58,360,523, or $0.67 per share, and an accumulated deficit of approximately $172.0 million as of December 31, 2009.
Where does Halozyme's revenue come from?
Most revenue comes from collaborative agreements: $12,700,458 of the $13,671,305 total in 2009. These include license fee and milestone amortization from Roche and Baxter, along with research and development reimbursements. Product sales were only $970,847 and come mainly from HYLENEX and Cumulase.
Does Halozyme have enough cash to operate?
Management believes current cash and cash equivalents of $67,464,506 will be sufficient for at least the next twelve months. However, it does not expect revenues to fund operations for at least several years and may need to raise additional capital through financing vehicles that include public offerings, collaborations, and private or debt financings.
What are the key drivers of Halozyme's spending?
Research and development expenses were $56.6 million in 2009, up from $44.2 million in 2008. The filing attributes the increase mainly to the ultrafast insulin program ($10.5 million higher) and the PEGPH20 program ($2.9 million higher). From January 2007 through December 2009, about 20% and 15% of R&D expenses were tied to the ultrafast insulin and PEGPH20 programs, respectively.
What are the main risks for investors?
The filing highlights dependence on partners and contract manufacturers (Avid and Cook) for API supply, the lack of any product candidate currently in the NDA approval process, uncertain FDA approval timing, possible dilution from future financings, and the potential effect of shelf-registration sales on the stock price.
06—Continue